A review of the incidence of nephrolithiasis among postmenopausal women receiving estrogen monotherapy or estrogen in combination with progestin suggests that HT increases the risk of stone formation.
A review of the incidence of nephrolithiasis among postmenopausal women receiving estrogen monotherapy or estrogen in combination with progestin suggests that HT increases the risk of stone formation, according to researchers at the University of Texas Southwestern Medical Center.
The study involved more than 27,000 healthy postmenopausal women from 40 US clinical centers participating in the Women's Health Initiative HT trials. Approximately 11,000 of the women had undergone a hysterectomy and were randomized to receive either 0.625 mg/d conjugated equine estrogens or placebo.
The remaining women who had not received a hysterectomy were randomized to receive either conjugated equine estrogens plus progestin (2.5 mg/d medroxyprogesterone acetate) or placebo. The women were followed for an average of 6 years.
Maalouf NM, Sato AH, Welch BJ, et al. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med. 2010;170(18):1678-1685.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More